Imperial College London
Portrait Picture

Dr John S Tregoning

Faculty of Medicine, Department of Infectious Disease

Professor in Vaccine Immunology
 
 
 
//

Contact

 

john.tregoning Website

 
 
//

Location

 

456 (Shattock Group)Wright Fleming WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Lindsey:2019:10.1016/S2213-2600(19)30086-4,
author = {Lindsey, BB and Jagne, YJ and Armitage, EP and Singanayagam, A and Sallah, HJ and Drammeh, S and Senghore, E and Mohammed, NI and Jeffries, D and Höschler, K and Tregoning, JS and Meijer, A and Clarke, E and Dong, T and Barclay, W and Kampmann, B and de, Silva TI},
doi = {10.1016/S2213-2600(19)30086-4},
journal = {Lancet Respiratory Medicine},
pages = {665--676},
title = {Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study},
url = {http://dx.doi.org/10.1016/S2213-2600(19)30086-4},
volume = {7},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: The efficacy and effectiveness of the pandemic H1N1 (pH1N1) component in live attenuated influenza vaccine (LAIV) is poor. The reasons for this paucity are unclear but could be due to impaired replicative fitness of pH1N1 A/California/07/2009-like (Cal09) strains. We assessed whether an updated pH1N1 strain in the Russian-backbone trivalent LAIV resulted in greater shedding and immunogenicity compared with LAIV with Cal09. METHODS: We did an open-label, prospective, observational, phase 4 study in Sukuta, a periurban area in The Gambia. We enrolled children aged 24-59 months who were clinically well. Children received one dose of the WHO prequalified Russian-backbone trivalent LAIV containing either A/17/California/2009/38 (Cal09) or A/17/New York/15/5364 (NY15) based on their year of enrolment. Primary outcomes were the percentage of children with LAIV strain shedding at day 2 and day 7, haemagglutinin inhibition seroconversion, and an increase in influenza haemagglutinin-specific IgA and T-cell responses at day 21 after LAIV. This study is nested within a randomised controlled trial investigating LAIV-microbiome interactions (NCT02972957). FINDINGS: Between Feb 8, 2017, and April 12, 2017, 118 children were enrolled and received one dose of the Cal09 LAIV from 2016-17. Between Jan 15, 2018, and March 28, 2018, a separate cohort of 135 children were enrolled and received one dose of the NY15 LAIV from 2017-18, of whom 126 children completed the study. Cal09 showed impaired pH1N1 nasopharyngeal shedding (16 of 118 children [14%, 95% CI 8·0-21·1] with shedding at day 2 after administration of LAIV) compared with H3N2 (54 of 118 [46%, 36·6-55·2]; p<0·0001) and influenza B (95 of 118 [81%, 72·2-87·2]; p<0·0001), along with suboptimal serum antibody (seroconversion in six of 118 [5%, 1·9-10·7]) and T-cell responses (CD4+ interferon γ-positive and/or CD4+ interleukin 2-positive
AU  - Lindsey,BB
AU  - Jagne,YJ
AU  - Armitage,EP
AU  - Singanayagam,A
AU  - Sallah,HJ
AU  - Drammeh,S
AU  - Senghore,E
AU  - Mohammed,NI
AU  - Jeffries,D
AU  - Höschler,K
AU  - Tregoning,JS
AU  - Meijer,A
AU  - Clarke,E
AU  - Dong,T
AU  - Barclay,W
AU  - Kampmann,B
AU  - de,Silva TI
DO  - 10.1016/S2213-2600(19)30086-4
EP  - 676
PY  - 2019///
SN  - 2213-2600
SP  - 665
TI  - Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study
T2  - Lancet Respiratory Medicine
UR  - http://dx.doi.org/10.1016/S2213-2600(19)30086-4
UR  - https://www.ncbi.nlm.nih.gov/pubmed/31235405
UR  - https://www.sciencedirect.com/science/article/pii/S2213260019300864?via%3Dihub
UR  - http://hdl.handle.net/10044/1/71063
VL  - 7
ER  -
Download